摘 要:依鲁替尼是一种针对B-细胞恶性肿瘤的抗癌药物。依鲁替尼合成物的关键手性中间体是(S)-N-BOC-3-羟基哌啶醇((S)-NBHP),它能通过酮还原酶(KRED)催化生物还原产生。本课题是对重组醇脱氢酶的分子模拟以及重组醇脱氢酶生物催化合成抗肿瘤药物中间体反应应优化进行研究,提高反应产率。通过对底物1-N-Boc-3-哌啶酮进行分子模拟获得其可能的分子结构进而探索其具有的物理与化学性质。系统地探究助溶剂及其浓度、葡萄糖与底物浓度比、底物浓度、pH值和温度对重组醇脱氢酶生物催化合成抗肿瘤药物中间体反应产率的影响。确定每一种影响因素的最适条件,以使生物催化反应达到最高的转化率。最后分子对接结构较为理想,所确定下来的最适反应条件为:助溶剂及其浓度为5%的甲醇、辅底物葡萄糖与底物摩尔比为1、pH=8。0的磷酸盐溶液作缓冲液、50℃下反应。77559
毕业论文关键词:重组醇脱氢酶;生物催化;分子模拟;反应优化
Molecular simulation of recombinant alcohol dehydrogenase and its catalytic synthesis of antitumor drug intermediates
Abstract: Ibrutinib is an anticancer drug targeting B-cell malignancies。 The key chiral intermediate for ibrutinib synthesis is the alcohol (S)-N-BOC-3-hydroxypiperidine ((S)-NBHP), which can be produced via ketore-ductase (KRED)-catalyzed bioreduction。 This paper proposed the Molecular simulation of recombine alcohol dehydrogenase and its catalytic synthesis of antitumor drug intermediates。 The molecular structure of 1-Boc-3- piperidone was obtained by molecular simulation, and its physical and chemical properties were explored。 The effects of cosolvent and its concentration, the ratio of glucose to substrate concentration, substrate concentration, pH value and temperature on the synthesis of the antitumor activity of alcohol dehydrogenase were investigated。 The optimal conditions for each factor were determined step by step to achieve the highest conversion rate。 Finally, the optimum reaction conditions were as follows: 5% methanol as the solvent,the ratio of glucose to substrate concentration is 1, Phosphate buffer with pH condition of pH=8。0,the reaction temperature is 50 degree。
Key words:Recombinant alcohol dehydrogenase;Biocatalysis;Molecular simulation;Response optimization
目录
1 研究背景 1
1。1 分子模拟的原理与应用 1
1。1。1 分子模拟的原理 1
1。1。2 分子对接的化学机理 1
1。1。3 分子模拟的应用 1
1。2 生物催化合成手性药物 2
1。2。1 生物催化的意义 2
1。2。2 手性化合物的研究现状 3
1。2。3 手性药物中间体依鲁替尼的合成方法 3
1。2。3。1 依鲁替尼简介 3
1。2。3。2 (S)-N-BOC-3-羟基哌啶的合成 4
1。3 本课题研究意义与内容 5
1。3。1 研究意义 5
1。3。2 研究内容 5
1。3。2。1 重组醇脱氢酶的分子模拟 5
1。3。2。2 重组醇脱氢酶催化合成抗肿瘤药物中间体的反应优化 6 重组醇脱氢酶的分子模拟及其催化合成抗肿瘤药物中间体的研究:http://www.youerw.com/yixue/lunwen_89149.html